Poor pain relief and possible toxicity from high-dose intrathecal opioid treatment: Report of two cases

Anca Popescu, MD; Rajorshi Mitra, MD; Jane Ballantyne, MD, FRCA

doi:10.5055/jom.2006.0007

Authors

Anca Popescu, MD
Rajorshi Mitra, MD
Jane Ballantyne, MD, FRCA

DOI:

https://doi.org/10.5055/jom.2006.0007

Keywords:

-

Abstract

-

Author Biographies

Anca Popescu, MD

Department of Neurology, Temple University Hospital, Philadelphia, Pennsylania.

Rajorshi Mitra, MD

Department of Physical Medicine and Rehabilitation, Stanford University Hospital, Stanford, California.

Jane Ballantyne, MD, FRCA

Chief, Division of Pain Medicine, Massachusetts General Hospital Pain Center, Department of Anesthesia and Critical Care, Harvard Medical School, Boston, Massachusetts.

References

Winkelmuller M, Winkelmuller W: Long term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg. 1996; 85: 458-467.

Doleys DM, Coleton M, Tutak U: Use of intraspinal infusion therapy with non-cancer pain patients: Follow up and comparison of workers compensation vs. non-workers compensation patients. Neuromodulation. 1998; 1: 149-159.

Roberts LJ, Finch PM, Goucke CR, et al.: Outcome of intrathecal opioids in chronic non-cancer pain. Eur J Pain. 2001; 5(4): 353-361.

Penn RD, Paice JA: Chronic intrathecal morphine for intractable pain. J Neurosurg. 1987; 67: 182-186.

Krames ES, Lanning RM: Intrathecal infusional analgesia for nonmalignant pain: Analgesic efficacy of intrathecal opioid with or without bupivacaine. J Pain Symptom Manage. 1993; 8: 539-548.

Kanoff RB: Intraspinal delivery of opiates by an implantable, programmable pump in patients with chronic, intractable pain of nonmalignant origin. J Am Osteopath Assoc. 1994; 94: 487-493.

Hassenbusch SJ, Stanton-Hicks M, Covington EC, et al.: Longterm intraspinal infusions of opioids in the treatment of neuropathic pain. J Pain Symptom Manage. 1995; 10: 527-543.

Paice JA, Penn RD, Shott S: Intraspinal morphine for chronic pain: A retrospective, multicenter study. J Pain Symptom Manage. 1996; 11: 71-80.

Angel IF, Gould HJ, Carey ME: Intrathecal morphine pump as a treatment option in chronic pain of nonmalignant origin. Surg Neurol. 1998; 49: 92-99.

Tutak U, Doleys DM: Intrathecal infusion systems for treatment of chronic low back and leg pain of noncancer origin. South Med J. 1996; 89: 295-300.

Anderson VC, Burchiel KJ: A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery. 1999; 44: 289-300.

Kumar K, Kelly M, Pirlo BA: Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy. Surg Neurol. 2001; 55: 79-88.

Thimineur MA, Kravitz E, Vodapally MS: Intrathecal opioid treatment for chronic non-malignant pain: A 3-year prospective study. Pain. 2004; 109: 242-249.

Schuchard M, Lanning R, North R, et al.: Neurologic sequelae of intraspinal drug delivery systems: Results of a survey of American implanters of implantable drug delivery systems. Neuromodulation. 1998; 1: 137-148.

Hassenbusch SJ, Portenoy RK, Cousins M, et al.: Polyanalgesic consensus conference 2003: An update on the management of pain by intraspinal drug delivery—Report of an expert panel. J Pain Symptom Manage. 2004; 27(6): 540-563.

Ballantyne JC, Mao J: Opioid therapy for chronic pain. N Engl J Med. 2003; 349: 1943-1953.

Portenoy RK, Savage SR: Clinical realities and economic considerations: Special therapeutic issues in intrathecal therapy— Tolerance and addiction. J Pain Symptom Manage. 1997; 14: S27-S35.

Feldberg W, Sherwood SL: Injections of drugs into the lateral ventricle of the cat. J Physiol. 1954; 123: 524-526.

Angst MS, Koppert W, Pahl I, et al.: Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain. 2003; 106(1-2): 49-57.

Hood DD, Curry R, Eisenach JC. Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicininduced hyperalgesia. Anesth Analg. 2003; 97(3): 810-815.

Guignard B, Bossard AE, Coste C, et al.: Acute opioid tolerance: Intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiol. 2000; 93(2): 409-417.

Wagner BK, O’Hara DA: Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients. Clin Pharmacokinet. 1997; 33(6): 426-453.

Parkinson SK, Bailey SL, Little WL, et al.: Myoclonic seizure activity with chronic high-dose spinal opioid administration. Anesthesiol. 1990; 72: 743-745.

Mao J: Opioid induced abnormal pain sensitivity: Implications in clinical opioid therapy. Pain. 2002; 100: 213-217.

Mao J, Sung B, Ji RR, et al.: Chronic morphine induces down regulation of spinal glutamate transporters: Implications in morphine tolerance and abnormal pain sensitivity. J Neurosci. 2002; 22: 8312-8323.

Mao J, Sung B, Ji RR, et al.: Neuronal apoptosis associated with morphine tolerance: Evidence for an opioid-induced neurotoxic mechanism. J Neurosci. 2002; 22: 7650-7661.

Cicero T: Effects of exogenous and endogenous opiates on the hypothalamic-pituitary-gonadal axis in the male. Fed Proc. 1980; 39(8): 2551-2554.

Genazzani AR, Genazzani AD, Volpogni C, et al.: Opioid control of gonadotrophin secretion in humans. Hum Reprod. 1993; 8(Suppl 2): 151-153.

Jordan D, Tafani JAM, Ries C, et al.: Evidence for multiple opioid receptors in the human posterior pituitary. J Neuroendocrinol. 1996; 8: 883-887.

Veldhuis JD, Rogol AD, Samojlik E, et al.: Role of endogenous opiates in the expression of negative feedback actions of androgen and estrogen on pulsatile properties of luteinizing hormone secretion in man. J Clin Invest. 1984; 74: 47-55.

Cicero TJ, Bell RD, Wiest WG, et al.: Function of the male sex organs in heroin and methadone users. N Engl J Med. 1975; 292(17): 882-887.

Mendelson JH, Mendelson JE, Patch VD: Plasma testosterone levels in heroin addiction and during methadone maintenance. J Pharmacol Exp Ther. 1975; 192: 211-217.

Mendelson JH, Meyer RE, Ellingboe J, et al.: Effects of heroin and methadone on plasma cortisol and testosterone. J Pharmacol Exp Ther. 1975; 195: 296-302.

Daniell HW: Narcotic-induced hypogonadism during therapy for heroin addiction . J Addictive Dis. 2002; 21(4): 47-53.

Fachinetti F, Volpe A, Farci G, et al.: Hypothalamus-pituitary-adrenal axis of heroin addicts. Drug Alcohol Depend. 1985; 15: 361-366.

Khan C, Malik SA, Iqbal MA: Testosterone suppression by heroin. J Pak Med Assoc. 1990; 40(7): 172-173.

Bliesener N, Albrecht S, Schwager A, et al.: Plasma testosterone and sexual function in men on buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2004; 90(1): 203-206.

Daniell HW: Hypogonadism in men consuming sustainedaction oral opioids. J Pain. 2002; 3(5): 377-384.

Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al.: Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004; 100(4): 851-858.

Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al.: Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy. J Pain Symptom Manage. 2003; 26(5): 1055-1061.

Abs R, Verhelst J, Maeyaert J, et al.: Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000; 85(6): 2215-2222.

Finch PM, Roberts LJ, Price L, et al.: Hypogonadism in patients treated with intrathecal morphine. Clin J Pain. 2000; 16(3): 251-254.

Gijbels J, Erdine S, Maeyaert J, et al.: Neuromodulation of pain. A consensus statement of the European Federation of IASP chapters (EFIC). Eur J Pain. 1998; 2: 203-209.

Roberts LJ, Finch PM, Pullan PT, et al.: Sex hormone suppression by intrathecal opioids: A prospective study. Clin J Pain. 2002; 18(3): 144-148.

Daniell HW: The association of endogenous hormone levels and exogenously administered opiates in males. Am J Pain Manage. 2001; 11(1): 8-10.

Pelosi MA, Sama JC, Caterini H, et al.: Galactorrhea-amenorrhea syndrome associated with heroin addiction. Am J Obstet Gynecol. 1974; 118(7): 966-970.

Paice JA, Penn RD: Amenorrhea associated with intraspinal morphine. J Pain Symptom Manage. 1995; 10: 582-583.

Banki CM, Arato M: Multiple hormonal responses to morphine: Relationship to diagnosis and dexamethasone suppression. Psychoneuroendocrinology. 1987; 12: 3-11.

Collu R, Clermont MJ, Ducharme JR: Effects of thyrotrophinreleasing hormone on prolactin, growth hormone and corticosterone secretions in adult male rats treated with pentobarbital or morphine. Eur J Pharmacol. 1976; 37: 133-140.

Lee C, Ludwig S, Duerksen D: Low serum cortisol associated with opioid use—Case report and review of literature. Endocrinologist. 2002; 12(1): 5-8.

Allolio B, Deuss U, Kaulen D, et al.: FK 33-824, a metenkephalin analog, blocks corticotropin-releasing hormoneinduced adrenocorticotropin secretion in normal subjects but not in patients with Cushing’s disease. J Clin Endocrinol Metab. 1986; 63: 1427-1431.

Taylor T, Dluhy RG, Williams GH: Beta-endorphin suppresses adrenocorticotropin and cortisol levels in normal human subjects. J Clin Endocrinol Metab. 1983; 57: 592-596.